Cashu
Capricor Therapeutics Faces Class Action Over Misleading Deramiocel Statements
2 days ago
Stocks
Health Care
capr
Capricor Therapeutics
NASDAQ: CAPR
+0.05 (0.00%)
6.335
USD
At close at Sep 03, 13:26 UTC
Overview
Loading chart...
Key Stats
Market Cap
289.33M
Dividend Yield
0.00%
P/E Ratio
-4.13
EPS
-1.15
Revenue
22.27M
Avg. Volume
1.01M
About
What does CAPR do?
Capricor Therapeutics, based in Beverly Hills, develops biological therapies for serious medical conditions, focusing on CAP-1002 for Duchenne muscular dystrophy in Phase 3 trials. The company also utilizes exosome technology for various therapeutic applications.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.